Home › Endometrial Cancer › Pennsylvania
Endometrial Cancer clinical trials in Pennsylvania
46 studies for Endometrial Cancer are looking for participants at sites in Pennsylvania.
Cities in Pennsylvania
- Philadelphia29 studies
- Pittsburgh24 studies
- Harrisburg6 studies
- Allentown5 studies
- York4 studies
- Erie3 studies
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- UPMC-Heritage Valley Health System Beaver, Beaver
- UPMC Hillman Cancer Center at Butler Health System, Butler
- UPMC Hillman Cancer Center - Passavant - Cranberry, Cranberry Township
- and 22 more
RecruitingPhase 2
Ages 18 and older · Women · Updated Nov 12, 2026 · NCT05112601Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
- NRG Oncology, Philadelphia
- University of Pennsylvania/Abramson Cancer Center, Philadelphia
- Thomas Jefferson University Hospital, Philadelphia
RecruitingPhase 1
Ages 18 and older · Women · Updated Nov 12, 2026 · NCT05950464A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
- Sidney Kimmel Cancer Center, Philadelphia
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07458347Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Lehigh Valley Hospital-Cedar Crest, Allentown
- UPMC Altoona, Altoona
- Lehigh Valley Hospital - Muhlenberg, Bethlehem
- and 18 more
RecruitingPhase 2
All ages · All sexes · Updated Nov 12, 2026 · NCT05564377Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
- Penn State Milton S Hershey Medical Center, Hershey
- Paoli Memorial Hospital, Paoli
- Thomas Jefferson University, Philadelphia
- and 2 more
RecruitingPhase 2
Ages 18 and older · Women · Updated Nov 12, 2026 · NCT05640999A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
- Asplundh Cancer Pavilion, Willow Grove
RecruitingPhase 3
Ages 18 and older · Women · Updated Nov 10, 2026 · NCT06340568A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- Univ of Pennsylvania, Abramson Cancer Center, Philadelphia
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07020221A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- St. Luke's University Health Network ( Site 6041), Bethlehem
- Hospital of the University of Pennsylvania ( Site 5007), Philadelphia
- AHN West Penn Hospital ( Site 6006), Pittsburgh
RecruitingPhase 3
Ages 18 and older · Women · Updated Nov 10, 2026 · NCT06952504Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
- UPMC Hillman Cancer Center Erie, Erie
- UPMC Cancer Centers - Arnold Palmer Pavilion, Greensburg
- Penn State Milton S Hershey Medical Center, Hershey
- and 7 more
RecruitingPhase 3
Ages 18 and older · Women · Updated Nov 6, 2026 · NCT07198074A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Sidney Kimmell Cancer Center - Jefferson Health, Philadelphia
RecruitingPhase 1
Ages 19 and older · All sexes · Updated Nov 5, 2026 · NCT06586957Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Alliance Cancer Specialist, Doylestown
- Allegheny Health Network, Pittsburgh
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT05579366A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- University of Pittsburgh Medical Center, Pittsburgh
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07114601Distance-Based Exercise to Preserve Function and Prevent Disability
- UPMC Hillman Cancer Center at Butler Health System, Butler
- UPMC Hillman Cancer Center - Passavant - Cranberry, Cranberry Township
- IRMC Cancer Center, Indiana
- and 6 more
Recruiting
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07059884Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
- Lehigh Valley Health Network (Data Collection Only), Allentown
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT04165772Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
- University of Pittsburgh Medical Center, Pittsburgh
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT07524322A Phase 1 Study of LNCB74 in Advanced Solid Tumors
- Sidney Kimmel Comprehensive Center at Jefferson, Philadelphia
- UPMC, Pittsburgh
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT06774963A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting
- Western Pennsylvania Hospital, Pittsburgh
RecruitingPhase 3
Ages 18 and older · Women · Updated Oct 27, 2026 · NCT07022483A Phase 1 Study of the Safety and Tolerability of CTX-10726
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 23, 2026 · NCT07419841A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- University of Pennsylvania / Abramson Cancer Center, Philadelphia
- Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Research Organization, Philadelphia
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT04657068A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Research Site, Pittsburgh
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT05123482DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
- Research Site, Hershey
- Research Site, Philadelphia
- Research Site, Pittsburgh
RecruitingPhase 3
Ages 18 and older · Women · Updated Oct 13, 2026 · NCT06989112Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 1
Ages 15 and older · All sexes · Updated Oct 9, 2026 · NCT06276491FOG-001 in Locally Advanced or Metastatic Solid Tumors
- University of Pennsylvania, Perelman School of Medicine, Philadelphia
- University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 7, 2026 · NCT05919264The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
- University of Pittsburgh Medical Center, Pittsburgh
- WellSpan York Cancer Center, York
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Oct 2, 2026 · NCT04585750Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Philadelphia
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05867251DESTINY-PANTUMOUR04
- Research Site, Philadelphia
RecruitingObservational study
Ages 18 to 130 · All sexes · Updated Sep 25, 2026 · NCT07124000A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
- Perelman School of Medicine at the University of Pennsylvania, Philadelphia
RecruitingPhase 1/2
Ages 18 and older · Women · Updated Sep 24, 2026 · NCT04590326Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Allegheny Health Network, Pittsburgh
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06128551PROton Therapy for Post Surgical Treatment of GYNecologic Cancer
- Lancaster General Health - Ann B. Barshinger Cancer Institute, Lancaster
- University of Pennsylvania, Philadelphia
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 17, 2026 · NCT05758688ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- University of Pennsylvania, Philadelphia
- WellSpan Medical Oncology & Hematology at York Cancer Center, York
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT05059444FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
- Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT07216105Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Children's Hospital of Philadelphia, Philadelphia
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh
RecruitingPhase 1/2
12 Months – 30 Years · All sexes · Updated Aug 25, 2026 · NCT04851119A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
- West Penn Hospital, Pittsburgh
RecruitingPhase 2
Ages 18 and older · Women · Updated Aug 21, 2026 · NCT05548296A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT04104776A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Philadelphia
- Normunity Investigational Site, Philadelphia
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT07182149A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
- SCRI - Sydney Kimmel Cancer Center - Jefferson Health, Philadelphia
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT07470853Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease
- Lehigh Valley Health Network, Allentown
RecruitingObservational study
Ages 18 and older · Women · Updated Aug 7, 2026 · NCT04291612Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
- Research Site, Bethlehem
- Research Site, Hershey
- Research Site, Lancaster
- and 5 more
RecruitingPhase 3
Ages 18 and older · Women · Updated Jul 29, 2026 · NCT07044336Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
- 127, Pittsburgh
RecruitingPhase 2
Ages 18 and older · Women · Updated Jul 16, 2026 · NCT06906341A Study of Lorigerlimab in Participants With Advanced Solid Tumors
- West Penn Allegheny Health, Pittsburgh
RecruitingPhase 2
Ages 18 and older · Women · Updated Jun 2, 2026 · NCT06730347From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.